Search Results - "Richman, Stephen P."

Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma by Feun, Lynn G., Li, Ying‐Ying, Wu, Chunjing, Wangpaichitr, Medhi, Jones, Patricia D., Richman, Stephen P., Madrazo, Beatrice, Kwon, Deukwoo, Garcia‐Buitrago, Monica, Martin, Paul, Hosein, Peter J., Savaraj, Niramol

“…Background Checkpoint inhibitors have shown modest activity in patients with advanced hepatocellular carcinoma (HCC). Herein, the authors report a prospective…”
Get full text

Levels of Symptom Burden During Chemotherapy for Advanced Lung Cancer: Differences Between Public Hospitals and a Tertiary Cancer Center by CLEELAND, Charles S, MENDOZA, Tito R, LU, Charles, WANG, Xin Shelley, WOODRUFF, Jeanie F, PALOS, Guadalupe R, RICHMAN, Stephen P, NAZARIO, Arlene, LYNCH, Garrett R, LIAO, Kai-Ping, MOBLEY, Gary M

“…We compared risk factors for high disease- and treatment-related symptom burden over 15 weeks of therapy in medically underserved patients with advanced…”
Get full text

Pain Education for Underserved Minority Cancer Patients: A Randomized Controlled Trial by ANDERSON, Karen O, MENDOZA, Tito R, KALISH, Dorianne, CLEELAND, Charles S, PAYNE, Richard, VALERO, Vicente, PALOS, Guadalupe R, NAZARIO, Arlene, RICHMAN, Stephen P, HURLEY, Judith, GNING, Ibrahima, LYNCH, Garrett R

“…Previous studies found that African American and Hispanic cancer patients are at risk for undertreatment of pain. We evaluated the efficacy of a pain education…”
Get full text

Cancer pain management among underserved minority outpatients: Perceived needs and barriers to optimal control by ANDERSON, Karen O, RICHMAN, Stephen P, HURLEY, Judith, PALOS, Guadalupe, VALERO, Vicente, MENDOZA, Tito R, GNING, Ibrahima, CLEELAND, Charles S

“…Minority patients with cancer are at risk for undertreatment of cancer-related pain. Most studies of patient-related barriers to pain control have surveyed…”
Get full text

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma by Feun, Lynn G, Wangpaichitr, Medhi, Li, Ying-Ying, Kwon, Deukwoo, Richman, Stephen P, Hosein, Peter J, Savaraj, Niramol

“…A phase II trial of pasireotide was performed to assess its efficacy and safety in advanced or metastatic hepatocellular carcinoma (HCC). Patients with…”
Get full text

Phase II trial of SOM230 in patients with unresectable hepatocellular carcinoma (HCC) by Feun, Lynn G., Savaraj, Niramol, Wangpaichitr, Medhi, Richman, Stephen P., Kwon, Deukwoo, Dinh, Vy, Martin, Paul

“…Abstract only…”
Get full text

Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma by Feun, Lynn G., Li, Ying-Ying, Wangpaichitr, Medhi, Jones, Patricia Denise, Richman, Stephen P., Madrazo, Beatrice, Kwon, Deukwoo, Martin, Paul, Hosein, Peter Joel, Savaraj, Niramol

“…Abstract only…”
Get full text

Minority cancer patients and their providers : Pain management attitudes and practice by ANDERSON, K. O, MENDOZA, T. R, CLEELAND, C. S, VALERO, V, RICHMAN, S. P, RUSSELL, C, HURLEY, J, DELEON, C, WASHINGTON, P, PALOS, G, PAYNE, R

“…The goals of the current studies were: 1) to determine the pain treatment needs of socioeconomically disadvantaged African-American and Hispanic patients with…”
Get full text

BCG Vaccine and Its Derivatives: Potential, Practical Considerations, and Precautions in Human Cancer Immunotherapy by Hersh, Evan M, Gutterman, Jordan U, Mavligit, Giora M, Reed, Richard C, Richman, Stephen P

“…BCG vaccine is undergoing extensive clinical trials for cancer immunotherapy. These studies are based on its immunopotentiating and macrophage-activating…”
Get full text

Epilesional Scarification: Preliminary Report of a New Approach to Local Immunotherapy With BCG by Richman, Stephen P, Mavligit, Giora M, Wolk, Richard, Gutterman, Jordan U, Hersh, Evan M

“…Because of the serious toxicity of intralesionally injected BCG, including high fever, local ulceration, chronic drainage, and disseminated BCG disease, 13…”
Get full text

Cancer pain management among underserved minority outpatients by Anderson, Karen O., Richman, Stephen P., Hurley, Judith, Palos, Guadalupe, Valero, Vicente, Mendoza, Tito R., Gning, Ibrahima, Cleeland, Charles S.

“…BACKGROUND Minority patients with cancer are at risk for undertreatment of cancer‐related pain. Most studies of patient‐related barriers to pain control have…”
Get full text

Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia by Gucalp, R, Ritch, P, Wiernik, P H, Sarma, P R, Keller, A, Richman, S P, Tauer, K, Neidhart, J, Mallette, L E, Siegel, R

“…This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate…”
Get more information

Ectopic adrenocorticotropic hormone syndrome associated with metastatic skin tumors and Cushing's syndrome by Izumi, A K, Richman, S P

Get more information

A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma by Morrell, Louise E., Lee, Young J., Hurley, Judith, Arias, Mayda, Mies, Carolyn, Richman, Stephen P., Fernandez, Hugo, Donofrio, Kim A., Raub, William A., Cassileth, Peter A.

“…BACKGROUND Traditionally, primary surgical therapy is considered unsuitable for the treatment of patients with locally advanced breast carcinoma (LABC)…”
Get full text

Minority cancer patients and their providers by Anderson, Karen O., Mendoza, Tito R., Valero, Vicente, Richman, Stephen P., Russell, Christy, Hurley, Judith, DeLeon, Cindy, Washington, Patricia, Palos, Guadalupe, Payne, Richard, Cleeland, Charles S.

“…BACKGROUND The goals of the current studies were: 1) to determine the pain treatment needs of socioeconomically disadvantaged African‐American and Hispanic…”
Get full text

Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas by Ardalan, B, Ucar, A, Reddy, R, Livingstone, A S, Markoe, A, Schwade, J, Richman, S P, Donofrio, K

“…Preclinical and clinical data suggest that N-phosphonacetyl-L-aspartic acid (PALA) can augment the cytotoxic effects of 5-fluorouracil (5-FU). In addition, the…”
Get more information

A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study by Morrell, L M, Bach, A, Richman, S P, Goodman, P, Fleming, T R, MacDonald, J S

“…Adenocarcinoma of the pancreas is a highly lethal malignancy and chemotherapy has had little impact on the natural history of this disease. PALA, used to…”
Get more information

A phase II trial of continuous-infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study by Whitehead, R P, Wolf, M K, Solanki, D L, Hemstreet, 3rd, G P, Benedetto, P, Richman, S P, Flanigan, R C, Crawford, E D

“…A multicenter, phase II trial of continuous-infusion interleukin 2 (IL-2) was done in the Southwest Oncology Group to evaluate the efficacy and safety of this…”
Get more information

A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics by Sridhar, K S, Samy, T S, Agarwal, R P, Duncan, R C, Benedetto, P, Krishan, A G, Vogel, C L, Feun, L G, Savaraj, N M, Richman, S P

“…A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory…”
Get more information

Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-Fluorouracil in advanced gastric adenocarcinoma : A Southwest Oncology Group study by MANINO, R. L, FLEMING, T. R, MORRELL, L. M, ARDALAN, B, RICHMAN, S. P, MACDONALD, J. S

“…N-(phosphonacetyl)-disodium L-aspartic acid (PALA) demonstrates a synergistic antitumor effect when combined with 5-Fluorouracil (5-FU) in in vitro studies. In…”
Get full text